Silybum

Silybum (Milk Thistle): A Comprehensive Reference

1. Identity

Botanical Classification and Nomenclature

Silybum marianum (L.) Gaertn. is a species of thistle bearing several common names, including milk thistle, blessed milkthistle, Marian thistle, Mary thistle, Saint Mary's thistle, Mediterranean milk thistle, and variegated thistle. It is an annual or biennial plant of the family Asteraceae. Its accepted synonym is Carduus marianus L., and it is classified as a member of the Asteraceae family.

This fairly typical thistle has red to purple flowers and shiny pale green leaves with white veins. Once native from Southern Europe through Asia, it has spread throughout the world. Milk thistle is an upright herb that can grow 30 to 200 cm (12 to 79 in) tall and has an overall conical shape. The milky white veins present on the leaves produce a milky fluid when broken, which is the origin of the common name "milk thistle."

The Active Constituent: Silymarin

Silymarin is a complex mixture of polyphenolic molecules, including seven closely related flavonolignans — silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin — and one flavonoid, taxifolin. The main component of S. marianum fruit extract (silymarin) is the flavonolignan silybin, which is not only the major silymarin element but also the most active ingredient of this extract, as confirmed in various studies.

Silybin's structure consists of two main units: the first is based on taxifolin; the second is a phenylpropanoid unit, specifically coniferyl alcohol. These two units are linked together into one structure by an oxetane ring.

The milk thistle fruit or seed has been reported to carry up to 1.0%–1.2% silybins, whereas standardized extracts of Silybum marianum can contain 50%–70% silybins depending on the extraction method, plant chemotypes, and agroclimatic region.

Other Chemical Constituents

Milk thistle (Silybum marianum) contains flavanolignans, flavonoids, and fixed oils based principally on linoleic and oleic acid. Additional active constituents present in the seeds include apigenin, silybonol, proteins, betaine, fixed oil, and free fatty acids.

Common Preparations and Dosage Forms

Commercial preparations of milk thistle include capsules, tablets, and liquid extracts, and also more advanced formulations such as phytosomes and liposomes, developed to increase silymarin bioavailability. The most important bioactive constituent in milk thistle is the mixture of flavanolignans called silymarin. Pharmacopoeial standards have been established for silymarin content; for example, the British Pharmacopoeia (BP) and United States Pharmacopoeia (USP) specify a minimum content of 1.5% for standardized preparations.

Numerous methods have been developed to enhance the bioavailability of silymarin, including novel formulations such as liposomes, effervescent tablets, nanocrystals, co-crystallization, and self-microemulsifying delivery systems (SMEDDS). A phospholipid complex of silymarin (phytosome) has been reported to have 4.6 times higher bioavailability compared to unformulated silymarin; furthermore, a self-microemulsifying drug delivery system was reported to provide 1.7–2.5 times higher silymarin area under the curve (AUC) than unformulated silymarin.

2. Traditional and Historical Use

Ancient Greece and Rome (1st Century AD)

Milk thistle has a long recorded medicinal history across Mediterranean and Near Eastern cultures. In the 1st century AD, Pedanius Dioscorides, a Greek physician serving in the Roman army, listed a plant called "silybum" in his medical text De Materia Medica. Medicinal uses included liver support and easing milk flow in nursing women. Later, Galen, another Greek physician and philosopher, provided further documentation — including preparations for various digestive issues.

The Roman naturalist Pliny the Elder also wrote about milk thistle in his Naturalis Historia, praising the plant for its benefits in treating liver and gallbladder disorders, further solidifying its reputation as a liver tonic.

In cases of food poisoning caused by hepatotoxic fungi, particularly Amanita species, preparations of milk thistle seeds were utilized as an antidotal remedy. Various plant parts were used for a variety of therapeutic purposes in traditional European folk medicine.

Medieval and Renaissance Europe

Medieval Greek and Arabic medical writers preserved and expanded the original documentation in De Materia Medica. Milk thistle also appears in other Byzantine and Arabic pharmacopoeias. During the Middle Ages and Renaissance, milk thistle was used as a traditional European herbal medicine, with many listings in apothecary treatments during the 12th–16th century.

During the Middle Ages, herbalists and healers expanded its use, applying it to treat conditions such as jaundice, liver congestion, and insect stings. In 1597, English herbalist John Gerard referred to it as "the best remedy against melancholy diseases," a term linked to liver disorders since the liver was traditionally seen as the seat of emotions. Pietro Andrea Mattioli's 1626 Book of Herbs recommended it for jaundice, while Lonicerus described its use for an inflamed liver in 1679.

17th–19th Century European Herbalism and German Medicine

By the 17th century, English herbalist Nicholas Culpeper was recommending milk thistle to cleanse the liver and spleen and to treat jaundice. Traditional German medicine embraced milk thistle for liver disorders, digestive complaints, and gallstone prevention. Milk thistle has been used by ancient physicians and herbalists to treat a range of liver and gallbladder diseases and to protect the liver against a variety of poisons.

Folklore and Naming

According to folk tradition, the white-veined appearance of the leaves was believed to have originated from the Virgin Mary's milk, giving the plant its common name and the species epithet marianum. The plant's name Silybum derives from the Greek word silybon, meaning "tassel" or "tuft," likely referring to its unique flower.

Milk thistle has a rich history of use in ancient Greek and Roman diets. The plant's leaves were prepared by removing their spines and incorporating them into salads or boiled as a vegetable, while stalks, roots, and flowers were cooked similarly to other greens.

3. Key Constituents and Mechanisms of Action

The Silymarin Complex

Silymarin is an amalgamation of flavonolignans derived from milk thistle, with silybin as its most active component. Available literature suggests that silymarin and silibinin have four distinct mechanisms of action: firstly, they function as antioxidants, scavengers, and regulators of intracellular glutathione levels; secondly, they act as stabilizers of cell membranes and regulators of permeability, preventing the entry of hepatotoxic agents into liver cells; thirdly, they promote the synthesis of ribosomal RNA, which stimulates liver regeneration; lastly, they inhibit the transformation of stellate hepatocytes into myofibroblasts, a process that contributes to the deposition of collagen and the development of liver cirrhosis.

Antioxidant Mechanisms

Silymarin's antioxidant defenses operate through multiple pathways. Primarily, it acts as a direct scavenger of free radicals. The phenolic hydroxyl groups present in silymarin's structure enable it to donate hydrogen atoms to free radicals, thereby neutralizing them and preventing oxidative damage. Studies have shown that silybin, a major component of silymarin, is effective in scavenging hypochlorous acid (HOCl) and hydroxyl radicals, although it is less effective against superoxide anions. This direct scavenging activity helps reduce the overall oxidative burden within cells.

Silymarin also activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, enhancing antioxidant enzyme expression and stabilizing mitochondrial membranes. Additionally, silymarin reduces the formation of reactive oxygen species (ROS) by chelating metal ions.

Anti-Inflammatory Mechanisms

Silymarin modulates the release of inflammatory mediators primarily by inhibiting signaling pathways such as NF-κB, TLR4, MAPK, and JAK-STAT3 pathways. It improves the inflammatory response by reducing the secretion of pro-inflammatory cytokines and enhancing the activity of anti-inflammatory agents. An anti-inflammatory effect of silymarin has been described in the liver tissue, in diabetes, and in experimental inflammatory bowel disease; there is evidence that silymarin regulates several inflammatory mediators such as TNF-α, interleukin (IL-1β, IL-6, and IL-1) receptor antagonists, and nitric oxide. Moreover, silymarin downregulates prostaglandin and leukotriene synthesis, inhibits cyclooxygenase II, reduces cytotoxic CD8 activity, and decreases neutrophil sequestration at sites of inflammation.

Hepatoprotective Mechanisms

Silymarin has both hepatoprotective and regenerative actions. The mechanism involves reduction of free radicals formed by toxins that damage cell membranes through lipid peroxidation and competitive inhibition through hepatocyte external cell membrane modification. Silymarin forms a complex that impedes the entrance of toxins into the interior of liver cells. Additionally, silymarin metabolically stimulates hepatic cells and activates the RNA biosynthesis of ribosomes to stimulate protein formation.

Analysis of silymarin suggests that the compound protects cells via processes that suppress cellular metabolism, activate stress pathways, and downregulate inflammatory signaling. Although preliminary laboratory studies found that silymarin exerted antiviral, anti-inflammatory, antioxidant, and liver-protective effects, researchers still do not fully understand why, and those benefits were not consistently seen in clinical trials of milk thistle for liver diseases.

Bioavailability Challenges

Poor bioavailability of silymarin, which leads to plasma concentrations far below the levels used in in vitro experiments, is a major impediment to translating preclinical findings into clinical benefit. Silymarin components suffer from poor solubility in water and lipid media, and their absorption in the intestine is rather limited. Moreover, silybin undergoes intensive Phase II metabolism and is rapidly excreted in bile and urine, leading to low therapeutic efficacy with standard formulations. After absorption, silymarin undergoes rapid phase II metabolism and is primarily excreted into bile and urine. It exhibits enhanced absorption in patients with hepatitis C and non-alcoholic fatty liver disease.

4. Scientific Evidence by Area of Use

4.1 Liver Disease — General Overview

Results from clinical trials of milk thistle for liver diseases, such as alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and liver problems caused by cancer chemotherapy, low oxygen levels, or toxins, have been conflicting or too limited to draw firm conclusions. There is not enough high-quality evidence to allow definite conclusions about the effects of milk thistle on health conditions in people.

4.2 Liver Enzyme Levels — Systematic Review Evidence

A systematic review following PRISMA 2020 guidelines identified 29 randomized clinical trials (RCTs), published between 1992 and 2023, that met inclusion criteria, encompassing 3,846 participants with diverse underlying conditions. A 2017 systematic review and meta-analysis of a total of 23 trials evaluated the effect of silymarin on serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (γGT) in patients with liver diseases. The authors concluded that silymarin minimally reduced the serum levels of ALT and AST; however, the results were without clinical relevance. They also noted the need for studies with more appropriate methodological designs.

4.3 Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

A trial involving 64 patients with NASH showed substantial reductions in ALT and AST levels after just eight weeks of treatment with 210 mg/day of silymarin. In addition to lowering liver enzyme levels, silymarin has been associated with histological improvements in liver conditions related to NAFLD. A double-blind, placebo-controlled trial reported significant reductions in fibrosis scores among patients treated with 700 mg/day of silymarin over 48 weeks, suggesting a potential role in slowing NAFLD progression.

In the context of NASH, silymarin intake ranging from 140 to 700 mg demonstrated safety and tolerability, with an improvement in hepatic steatosis and lobular inflammation observed in some subjects, although these changes did not reach statistical significance in histological improvement.

In a randomized, placebo-controlled trial in non-cirrhotic NASH patients, 4/27 (15%) in the 700 mg dose group, 5/26 (19%) in the 420 mg group, and 3/25 (12%) of placebo recipients reached the primary histological endpoint (p = 0.79), indicating no statistically significant benefit from silymarin in the intention-to-treat analysis. Silymarin (Legalon®) at the higher-than-customary doses tested in this study was determined to be safe and well tolerated.

4.4 Hepatitis C

No dietary supplement has been shown to be effective for hepatitis C. Several studies of silymarin (milk thistle) dietary supplements in people with hepatitis C did not find beneficial effects. Findings from the 2008 uncontrolled HALT-C study suggest that silymarin use by hepatitis C patients was associated with fewer and milder symptoms of liver disease and somewhat better quality of life, but there was no beneficial effect found on serum ALT or hepatitis C virus RNA levels. The finding of improved quality of life in patients taking silymarin was not confirmed in the more rigorous 2012 study described.

Although preclinical pharmacological benefits of silymarin seem promising, few have manifested in clinical studies. Higher-than-usual-dose silymarin failed to produce a satisfactory anti-hepatitis C virus (HCV) effect in a large randomized controlled trial. Due to the availability of direct antiviral drugs, the use of silymarin for viral hepatitis has not attracted much recent research attention; however, results imply that silymarin may be useful in supportive therapy.

4.5 Alcoholic Liver Disease and Cirrhosis

The use of 700 mg/day of silymarin for 48 weeks in patients with NASH exhibited a significant reduction in fibrosis and improvement in liver biochemistry. Similar beneficial effects of silymarin are observed at higher doses in patients with alcoholic cirrhosis and in improving associated metabolic endpoints and insulin resistance in patients with cirrhotic diabetes. The lower dose of silymarin (less than 140 mg three times a day) also caused a notable decrease in liver enzymes. Overall, based on clinical evidence, silymarin was found to be safe and well tolerated.

4.6 Toxic Liver Injury and Amanita Mushroom Poisoning

The addition of intravenous silibinin to aggressive intravenous fluid management serves to arrest and allow reversal of the manifestation of fulminant hepatic failure, even in severely poisoned patients. These findings, together with available clinical experience, justify the use of silibinin (as Legalon® SIL) in Amanita poisoning cases. Silibinin is thought to interfere with hepatic uptake of alpha-amanitin by blocking organic acid transporter protein 1B3 (OATP1B3), so early institution of therapy offers the best chance for clinical efficacy.

A series of 18 cases of Amanita phalloides poisoning was treated by combined chemotherapy during 1980 and 1981. After attempted primary elimination of the toxin, all patients received silybin as basic therapy mainly by infusion and, in two instances, silymarin orally. A close relationship was found between the severity of the intoxication and the time elapsed before commencement of silybin therapy. Administration of silybin within approximately 48 hours after mushroom intake appears to be an effective measure to prevent severe liver damage in Amanita phalloides poisoning.

4.7 Type 2 Diabetes Mellitus

In a systematic review and meta-analysis including five randomized controlled trials and 270 patients, silymarin administration determined a significant reduction in fasting blood glucose levels (−26.86 mg/dL; 95% CI −35.42–18.30) and HbA1c levels (−1.07; 95% CI −1.73–0.40) and had no effect on lipid profile. Being aware of the low quality of available evidence and elevated heterogeneity of these studies, no recommendation can be made and further studies are needed.

A meta-analysis of eight eligible publications from seven trials revealed that supplementation with silymarin can decrease fasting blood sugar, hemoglobin A1C, insulin, low-density lipoprotein cholesterol, and malondialdehyde, and can increase high-density lipoprotein cholesterol levels. However, silymarin did not have any significant effects on total cholesterol or triglyceride concentrations. The data suggest that silymarin supplements have beneficial effects on metabolic status and oxidative stress among patients with T2DM, but there is currently insufficient evidence to make firm conclusions about the full efficacy of supplementation.

Results from a small number of studies in people show that milk thistle extracts may help to control blood sugar in people with type 2 diabetes. Most of this research was done in Middle Eastern countries, and it is unclear whether the same results would be seen in other parts of the world.

4.8 Cancer — Preclinical and Limited Clinical Evidence

For more than 2,000 years, Silybum marianum L. (milk thistle) has been used for treating different complications such as jaundice, hepatitis, and cancers. It has also been shown that silymarin, a flavonolignan extract of the plant, demonstrates chemopreventive effects against cancers. Milk thistle and silymarin have been used as complementary treatments for cancers such as skin, prostate, and colorectal cancers, as well as hepatoprotective agents. Silymarin exerts a chemopreventive effect on reactivating cell death pathways by modulation of antiapoptotic proteins and synergizing with agonists of death domain receptors.

Treatment of melanoma cells with silybin attenuated the phosphorylation of extracellular signal-regulated kinase (ERK)-1/2 and RSK2. The blockade of MEK1/2-ERK1/2-RSK2 signaling by silybin resulted in the reduced activation of nuclear factor-kappa B (NF-κB), activator protein-1, and STAT3 — transcriptional regulators of several proliferative genes in melanomas. Silybin blocks the activation of these transcription factors and induces cell-cycle arrest at the G1 phase, which inhibits melanoma cell growth in vitro and in vivo. These findings are predominantly from preclinical (cell and animal) research and have not yet been validated in large human trials.

4.9 Neurological Conditions — Preclinical Evidence

Other studies have shown potential therapeutic effects of silymarin such as anticancer, anti-diabetic, anti-Alzheimer, and anti-Parkinson effects, so interest in researching this supplement remains high. Silymarin, extracted from the seeds of Silybum marianum, has been utilized in traditional medicine for many years and is recognized for its neuroprotective and hepatoprotective properties. Existing research reveals that silymarin has potent antioxidant and anti-inflammatory effects, coupled with anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory actions. The clinical evidence for neuroprotective effects in humans remains very limited and preliminary.

4.10 Cardiovascular Effects

In addition to its hepatoprotective properties, silymarin has been reported to be protective against oxidative stress and myocardial infarction caused by ischemia-reperfusion in rat cardiac tissues. Silymarin possesses cardioprotective effects through many mechanisms, including anti-inflammatory activity, improved antioxidant defense systems, free radical scavenging, membrane stabilizing, iron-chelating activity, and inhibition of apoptosis. These findings are primarily derived from animal studies; human clinical evidence for cardiovascular outcomes is limited.

5. Body Systems and Health Areas

• Hepatobiliary system: The most extensively studied application. Associated with hepatoprotection, antifibrotic effects, and support in conditions including NAFLD/NASH, alcoholic liver disease, drug-induced liver injury, and acute hepatotoxicity from amatoxin poisoning.
• Metabolic/Endocrine system: Investigated for blood glucose regulation and insulin sensitivity in type 2 diabetes; some evidence of effects on LDL-cholesterol.
• Immune and inflammatory system: Research reveals silymarin has potent antioxidant and anti-inflammatory effects, coupled with anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory actions.
• Neurological system: Preclinical signals suggesting potential neuroprotection and relevance to neurodegeneration; no established clinical benefit in humans.
• Oncology (adjunct/chemopreventive): Preclinical and some early-phase evidence for skin, prostate, and colorectal cancers; not yet established as clinical therapy.
• Cardiovascular system: Animal-model evidence for cardioprotection; clinical data are absent or very limited.
• Dermatological: Silymarin suppresses ultraviolet radiation A-induced oxidative stress, which can induce skin damage. Thus, topical application of silymarin can be a useful strategy for protecting against skin damage.

6. Dosage: Reported Ranges from Clinical Studies

The suggested dosage of silymarin has been used in clinical trials for up to 48 weeks at a dose of 2,100 mg/day and for up to 4 years at a dose of up to 420 mg/day.

• Chronic liver disease / cirrhosis: Daily doses of 420 mg up to 1,050 mg have been used, with some evidence that higher doses yield better results in more advanced disease.
• NASH (randomized trial): Eligible subjects were randomized to placebo or one of two dosages of Legalon® 420 mg or 700 mg administered orally three times daily.
• NASH (lower dose trial): A trial involving 64 patients with NASH used 210 mg/day of silymarin for eight weeks, with substantial reductions in ALT and AST levels.
• Chemotherapy-related liver injury: In oncology patients with chemotherapy-related liver injury, doses of 300 to 450 mg daily appeared to improve liver enzyme levels.
• Amanita poisoning (oral): Patients with hepatitis from Amanita poisoning were treated with oral silymarin doses ranging from 1.4 g/day to 4.48 g/day for a couple of days.
• High-dose safety study: Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks.
• Long-term high-dose study: Data from a 2017 clinical trial showed that patients were using silymarin at 2,100 mg/day for 48 weeks, with results showing that silymarin was well tolerated.

7. Safety Considerations and Drug Interactions

General Tolerability

Oral silymarin generally has few, if any, adverse effects and is well tolerated even at higher doses. Available evidence from clinical trials in people with liver diseases suggests that milk thistle is generally well tolerated. Side effects can include a laxative effect, nausea, diarrhea, abdominal bloating and pain, and occasional allergic reactions.

Some clinical studies have shown that individuals may experience nausea, dyspepsia, or mild diarrhea when taking more than 1,500 mg per day, though these are typical gastrointestinal reactions and symptoms disappear after discontinuing the dose.

Toxicological Profile

Silymarin has no major toxicity in animals. Silymarin was found to be mutagenic in Salmonella typhimurium strains in the presence of metabolic enzymes. However, silybin, silydianin, and silychristin were not cytotoxic or genotoxic at concentrations of 100 μM.

Allergic Reactions

Milk thistle may prompt an allergic reaction in individuals sensitive to the Asteraceae/Compositae plant family (e.g., ragweed, chrysanthemums, marigolds).

Drug Interactions and CYP450 Enzymes

Silymarin has a good safety profile, but relatively little is known regarding its potential for drug interaction. Silymarin has limited effect on the pharmacokinetics of several drugs in vivo, despite it decreasing the activity of cytochrome P-450 (CYP) enzymes, UDP-glucuronosyltransferase (UGT) enzyme, and reducing P-glycoprotein (P-gp) transport.

While there is some evidence of inhibitory effects of milk thistle extract on CYP450 and UGT activity in vitro, several reviews have concluded that the concentrations at which inhibition is observed are extremely high and generally not achievable with oral intake. Furthermore, these reviews concluded that, in clinical settings, there is limited influence of milk thistle extract on the pharmacokinetics of several drugs known to be metabolized by these enzymes, indicating no substantive interaction on several drug-metabolizing enzymes.

Milk thistle does not have any documented significant drug–drug interactions. However, since it does exert some effect on the CYP450 enzyme system, it might affect certain drugs, including diazepam and warfarin. Silymarin has low drug interactions, and it does not have major effects on cytochromes P-450. Some studies demonstrated that the use of silymarin must be exercised with caution when co-administered with narrow therapeutic window drugs.

Glycemic Interaction

Caution is warranted for patients with diabetes, as silymarin may slightly lower blood sugar, so combining it with insulin or anti-diabetic drugs could increase the risk of hypoglycemia.

Pregnancy and Pediatric Use

None of the available clinical studies adequately addressed the safety of milk thistle extract in children or pregnant/breastfeeding individuals. The lack of well-conducted developmental toxicity studies in animals, as well as the paucity of relevant clinical data, supports cautionary labelling for supplemental use. One clinical trial showed silymarin is safe in pregnancy with no anomalies, but caution should be exercised during pregnancy and more studies are needed, particularly in humans.

Regulatory Status

Currently, herbal products such as milk thistle in the United States are not considered drugs and do not have the same level of regulation as drugs from the U.S. Food and Drug Administration (FDA). Like most herbal products, the FDA does not approve or recommend milk thistle as a treatment for any medical condition.

Product Quality Concerns

Commercial preparations do not always contain the recommended concentrations of silymarin, failing to provide the expected therapeutic effect. While the poor quality of raw material may explain the low concentrations of silymarin, its deliberate removal is suspected to be an adulteration in some cases.

Overall Clinical Evidence Assessment

Healthcare workers, including physicians, nurse practitioners, nursing staff, and pharmacists, should be aware that currently there is no firm clinical evidence to recommend silybin or silymarin in the clinical setting. Silymarin offers protective effects on the liver and shows promise in improving liver function and histological outcomes in various chronic liver conditions. Despite these promising results, further research is needed to fully elucidate optimal dosing regimens, long-term safety, and potential drug interactions.

References

• NCCIH — Milk Thistle: Usefulness and Safety
• NCCIH — Hepatitis C and Dietary Supplements: What the Science Says
• NCCIH — Study of Milk Thistle's Effects Highlights a Two-Phase Process
• AHRQ — Milk Thistle: Effects on Liver Disease and Cirrhosis (Evidence Report Summary, NCBI Bookshelf)
• StatPearls — Milk Thistle (NCBI Bookshelf, NIH)
• PMC — Silybin, a Major Bioactive Component of Milk Thistle: Chemistry, Bioavailability, and Metabolism
• PMC — Hepatoprotective Effect of Silymarin
• PMC — Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review
• PMC — Role of Silymarin as Antioxidant in Clinical Management of Chronic Liver Diseases
• PMC — The Clinical Anti-Inflammatory Effects and Underlying Mechanisms of Silymarin
• PMC — A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin
• PMC — Silymarin as a Phytopharmaceutical Agent: Advances in Mechanistic Insights, Formulation Strategies, and Pre-Clinical Applications
• PMC — A Review of Therapeutic Potentials of Milk Thistle (Silybum marianum L.) and Its Main Constituent, Silymarin, on Cancer, and Their Related Patents
• PMC — Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
• PMC — Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review
• PMC — Metabolism, Transport and Drug–Drug Interactions of Silymarin
• PMC — Legalon® SIL: The Antidote of Choice in Patients with Acute Hepatotoxicity from Amatoxin Poisoning
• PMC — Clinical Characteristics and Outcome of Toxicity from Amanita Mushroom Poisoning
• PubMed — Safety and Toxicity of Silymarin, the Major Constituent of Milk Thistle Extract: An Updated Review
• PubMed — Drug-Drug Interactions of Silymarin on the Perspective of Pharmacokinetics
• PMC — Silymarin in Non-Cirrhotics with Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
• ScienceDirect — Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations
• Wiley — Silymarin: Unveiling its Pharmacological Spectrum and Therapeutic Potential in Liver Diseases
• ScienceDirect — The Effects of Silymarin Supplementation on Metabolic Status and Oxidative Stress in Patients with T2DM: A Systematic Review and Meta-Analysis
• PMC — Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial
• Health Canada — Summary of Health Canada's Safety Assessment of Milk Thistle Seed Extract
• PMC — Cardioprotective and Hepatoprotective Potential of Silymarin in Paracetamol-Induced Oxidative Stress
• Wikipedia — Silybum marianum
• Wikipedia — Silybum (genus)